Once completed in the third quarter of 2010, the 3.2 million USDfactory will turn out high-quality pharmaceutical products for cancer,diabetes, hypertension, and heart disease treatment.
The factory is part of an investment and technological transfercooperation agreement signed between Danapha and AQP. Danapha is theparent company of the joint venture, holding 51 percent of its stake,while the US partner possesses 24 percent and the VietnamPharmaceutical Corp (Vinapharm) owns 25 percent./.